{'fraction_non_alphanumeric': 0.04108309990662932, 'fraction_numerical': 0.02334267040149393, 'mean_word_length': 4.922651933701657, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Prediction of relapse-free period after radio- and chemotherapy in patients with breast cancer].

The study was carried out in 55 females with breast cancer stage III-IV, aged 35-77 yrs. The patients received radiation and standard courses of CMF, or CAF, or CMF+trastuzumab, or carboplatin+vepesid, or taxotere+epirubicin, or mustoforan. Radiation was administered in fractionated single focal doses of 3 Gy. S-index was determined before treatment started by an original short (ca. 4 hrs) method of evaluating apoptotic leukocyte DNA disintegration after ex vivo test irradiation as described by Ivanov S.D. et al., 2003. The index ranged 0.40-1.44 rel. units thus correlating with 2-100 month relapse-free period. Direct correlations were identified between S-index and relapse-free period for different regimens of radiochemotherapy. S-index level in excess of 0.95 involved relatively longer relapse-free survival. In summary, our method offers means of predicting the effectiveness of a particular regimen prior to treatment thus making individualization possible.